Ted Hull

Bako Diagnostics has appointed Ted Hull its CEO, effective Aug. 1. He succeeds Larry McCarthy who served as interim CEO and is Bako's chairman. Hull has more than 25 years of industry experience including 15 years at Genova Diagnostics where he was CFO then chairman and CEO. He was most recently managing partner of Ramble Ventures. 

Bako provides diagnostic and therapeutic services to the podiatric medical community with a focus on pathology for the lower extremity. Its testing menu includes epidermal nerve fiber density analysis, mass spectrometry for the identification of bacteria from culture specimens, and molecular genetics for detecting microorganisms and as a diagnostic aid in certain pathologic diagnoses.